So far, concentrations of CCL20, CXCL8 and CXCL10 in serum and in the cerebrospinal fluid (CSF) of MS patients have been analyzed sporadically, using a diverse methodology and comparison groups, so currently available data are not conclusive [34,35]. This evidence concerns the gene CXCL8 and myeloid sarcoma.